A Phase II Study of TRC105 in Patients With Hepatocellular Carcinoma (HCC) Who Have Progressed on Sorafenib.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Carotuximab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 18 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 13 May 2015 As per a TRACON pharmaceuticals media release, National Cancer Institute (NCI) reported positive results from this study at the 2015 ASCO Gastrointestinal Cancers Symposium.
- 16 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.